Despite underperforming the market over the past year, Medtronic still enjoys fairly upbeat outlook from analysts.

The pharma company's newer immunology drugs, Skyrizi and Rinvoq, have delivered robust sales growth that's proving to be the ...

A Medtronic hypertension procedure that can provide last-resort treatment for a condition that affects nearly half of all U.S ...

Medtronic (NYSE: MDT) announced that Gregory L. Smith, EVP, enterprise operations, notified the company of his decision to ...

Press Release  Medical technology leader, Medtronic has successfully concluded the UK leg of its European ACM2U Truck ...

National Medicare coverage paves the way for a larger patient population to access the blood pressure treatment, which gained ...

An announcement from Medtronic ( ($MDT) ) is now available. On November 1, 2025, Medtronic announced the retirement of Gregory L. Smith, Executive ...

Cardiac mapper turned treatment of his own heart condition into a new career NORTHAMPTON, MA / ACCESS Newswire / November 3, 2025 / David Stalls thought the dangerous heart rhythm problem that plagued ...

PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...

The CGM market is an exciting, fast-growing, multibillion-dollar medtech sector, according to our new Medtech Market ...

In the most recent trading session, Medtronic (MDT) closed at $91.73, indicating a -1.61% shift from the previous trading day.

With its stock down 4.5% over the past month, it is easy to disregard Medtronic (NYSE:MDT). To decide if this trend could ...